Any new or unusual symptom after dosing. Because this compound has little or no human safety data, there is no established list of 'expected' effects to reassure you against — treat anything abnormal as a signal.
Stop at the first clearly abnormal reaction and reassess. Keep the vial and lot number in case you need to describe what you actually took.
Any severe or fast-worsening symptom — difficulty breathing, chest pain, fainting, severe pain — is a 911 call regardless of the compound.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
A 15-amino-acid sequence derived from a partial sequence of human gastric juice protein BPC. No single receptor has been validated. The most cited proposed mechanisms are upregulation of VEGFR2 signalling and consequent angiogenesis, interaction with the nitric oxide system, and modulation of growth factor expression at injury sites. Mechanistic understanding remains genuinely incomplete — this is a peptide whose popularity substantially exceeds its mechanistic characterisation.
The preclinical literature is large: rodent models report accelerated healing of tendon, ligament, muscle, bone, and gastrointestinal mucosa, with much of it originating from a small number of affiliated research groups. Adequate, well-controlled human trials are absent. A related molecule (PL 14736) entered early clinical study for inflammatory bowel disease and did not proceed to approval. The gap between rodent findings and demonstrated human benefit is the central fact about BPC-157.
Not FDA-approved. No USP monograph. Placed in 503A Category 2 in September 2023 — substances that may present significant safety risks — barring compounding. Removed from Category 2 in April 2026 after the nomination was withdrawn, but not added to Category 1, leaving it neither expressly permitted nor prohibited. FDA's Pharmacy Compounding Advisory Committee was scheduled to consider BPC-157 (free base) and BPC-157 acetate for the 503A Bulks List at its July 23–24, 2026 meeting. This status is actively moving; verify before relying on anything here. Prohibited in sport (WADA S0).
Rodent toxicity studies report wide margins, and that is genuinely the extent of it. There is no long-term human safety data. Because a principal proposed mechanism is angiogenesis, the theoretical concern raised repeatedly by regulators and clinicians is that a pro-angiogenic agent may act on tissue you did not intend to grow. That concern is unresolved, not disproven — and it is why the substance drew Category 2 designation.
No human trial has ever established a dose for this compound. Any figure circulating online is extrapolated from animal studies or copied between vendors — it was not validated in people. That absence is the single most important dosing fact on this page. The related molecule PL-14736 was studied intrarectally for ulcerative colitis; systemic BPC-157 dosing in humans has never been trialled.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.